SecBot SecBot

Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

H.R. 1796 Rep. John James (R-MI-10) In committee
Bill text PDF
  1. Introduced Mar 3
  2. Committee Mar 3
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Mar 3, 2025Next: House vote
604d ago Mar 3, 2025: Referred to the House Committee on Energy and Commerce.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
1company, 6 filings
Subscribe to see spend
Member trades
0trades in the last 90 days
None in these companies
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

1 company
Companies by sector
Biotech & Pharma 1
Search all 1 companies, their asks and price moves Subscribe

Summary

This bill amends the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program. It updates the program's focus and funding.

Sec. 2, Sickle cell disease treatment prevention and treatment: This section makes several changes to the existing program. It shifts the program's focus from 'prevention and treatment of sickle cell disease' to 'treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease.' It also expands the ways the Secretary can work with entities, from only entering into a contract to also making a grant or entering into a cooperative agreement. Finally, it reauthorizes funding at $8,205,000 for each of fiscal years 2025 through 2029, replacing the previous authorization of $4,455,000 for fiscal years 2019 through 2023.

Summary of the bill text as introduced in House (Mar 3, 2025), generated by SecBot from the official bill text; the Library of Congress summary is not yet published.

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.